Array Biopharma to Report Financial Results for the First Quarter of Fiscal 2018 On October 31, 2017



BOULDER, Colo., Oct. 24, 2017 /PRNewswire/ -- Array BioPharma, Inc. will report financial results for the first quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, October 31, 2017. Ron Squarer, Chief Executive Officer, will lead the call.

    Date:                  Tuesday, October 31, 2017

    Time:                  9:00 a.m. Eastern Time

    Toll-Free:             (844) 464-3927

    Toll:                  (765) 507-2598

    Pass Code:                                94698561

Webcast, including Replay and Conference Call Slides:

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

    CONTACT:                          Tricia Haugeto

                                      Array BioPharma Inc.

                                      (303) 386-1193



View original content with multimedia:

SOURCE Array BioPharma Inc.

Company Codes: NASDAQ-NMS:ARRY

Back to news